Crush injury

Legal-Bay Lawsuit Funding Spearheads New Department to Focus on Construction Accidents and Lawsuits Involving New York Labor Law and Texas Gulf of Mexico Jones Act

Retrieved on: 
Wednesday, October 18, 2023
Falls, NP-hardness, Element, Slip, Burns, Explosion, Chronic pain, Personal injury, Bone, Construction, Workplace, Head injury, Lawsuit, Crush injury, Injury, Rachel Flowers, Accident, Electrocution, Fire, Health insurance, Insurance

HOUSTON, Oct. 18, 2023 /PRNewswire/ -- Legal-Bay LLC, The Lawsuit Pre-Settlement Funding Company, announced today that they are spearheading a new, specialized department to tackle the majority of lawsuit funding requests they've recently received for hard workers injured in construction site accidents, manual labor accidents, personal injury incidents involving heavy duty equipment, Jones Act worker's comp. and Fela cases, some of which fall under N.Y. labor law personal injury. These work-related cases include various injuries and elements such as collisions, demolition injury, crush injury, equipment malfunction, electrocution, slip and fall, gas leak, trench collapse, ground collapse, explosions, crane incidents, burns, falls, tree falls, shoulder injuries, back injuries, slipped discs, bone fractures, broken bones, fires, head injury, and traumatic brain injury. Also, damages can be rewarded due to the simple fact that you can no longer work and have lost wages or loss of wage claims.

Key Points: 
  • Lawsuit Cash Advance Firm shifts gears in market and branches out to niche cases involving workplace accidents and labor law violations nationally.
  • and Fela cases, some of which fall under N.Y. labor law personal injury.
  • Legal-Bay—a leader in lawsuit funding services and legal funding and a champion for plaintiffs—funds all types of workplace accident cases.
  • According to labor laws in place in most states, workers are entitled to safe working conditions on their job site.

Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model

Retrieved on: 
Tuesday, February 1, 2022
Eye, Patient, Pathology, Cell, Neurodegeneration, Glaucoma, ONC, HIV disease progression rates, SAN, IOP, Optic nerve, Brain, Crush injury, RGC, Severe cognitive impairment, Research, Death, OTCQB, Intraocular pressure, Cannabinoid, Electrophysiology, Disease, Animal, Biomarker, GLOBE, THC, Perg, RATS, Royal, CA, Pharmaceutical industry, Medical imaging

Glaucoma is a neurodegenerative disease of RGCs associated with degeneration of the optic nerve that leads to vision loss.

Key Points: 
  • Glaucoma is a neurodegenerative disease of RGCs associated with degeneration of the optic nerve that leads to vision loss.
  • This study was conducted using an aggressive optic nerve crush (ONC) model in rats to evaluate the neuroprotective potential of SBI-100.
  • Skye Bioscience Inc. is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary, cannabinoid-derived molecules to treat diseases with significant unmet needs.
  • The companys lead program, SBI-100, is focused on treating glaucoma, a disease with no cure and the worlds leading cause of irreversible blindness.

Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular Vessels

Retrieved on: 
Thursday, August 19, 2021
Constellation, Vibration, Proxy, Intention, SEC, Food, Authorization, Hospital, Review, Securities Act of 1933, Risk, Medicine, Fast track (FDA), Crush injury, U.S. Securities and Exchange Commission, EDT, Moyamoya disease, AHAC, Special, Time, Forward-looking statement, Investment, Prospectus, PIPE, Sale, Technology, Regulation of tobacco by the U.S. Food and Drug Administration, Form, Dialysis, Tissue, Nasdaq, Person, Perfusion, EAP, Failure, HAV, FDA, Security (finance), PAD, Business architecture, Company, Terminology, Webcast, Special access program, MPA, Acquisition, Amputation, GLOBE, Leg, Injury, Form S-4, Patient, COVID-19, Pharmaceutical industry

The patient received the HAV to restore blood flow to her crushed limb and avoid amputation.

Key Points: 
  • The patient received the HAV to restore blood flow to her crushed limb and avoid amputation.
  • On August 24, 2021, AHAC will hold a special shareholders meeting to vote on the proposed business combination with Humacyte.
  • Human Acellular Vessels (HAV) are engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.
  • Humacytes initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease.